Juvenile idiopathic arthritis (JIA) was the most frequent indication for anti-TNFα treatment (74.7 %, 195 treatments in 163 patients); other indications included inflammatory bowel disease (19.1 %, 50 treatments in 46 patients) and idiopathic uveitis (4.2 %, 11 treatments in 8 patients) (Table 1). Here, TNF is linked to inflammatory bowel disease.